Paul Rutgeerts
Rutgeerts, Paul
VIAF ID: 245511563 (Personal)
Permalink: http://viaf.org/viaf/245511563
Preferred Forms
- 100 0 _ ‡a Paul Rutgeerts
- 100 1 _ ‡a Rutgeerts, Paul
-
- 100 1 _ ‡a Rutgeerts, Paul
-
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Advances in inflammatory bowel diseases | |
Dry preparation for virtual CT colonography with fecal tagging using water-soluble contrast medium: initial results | |
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. | |
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. | |
Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data | |
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum | |
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis | |
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1 | |
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy | |
Effect of arabinoxylo-oligosaccharides on proximal gastrointestinal motility and digestion in healthy volunteers | |
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum | |
Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease | |
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial | |
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. | |
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease | |
Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro | |
Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model | |
Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease | |
Effects of interleukin 4 on CD25+CD4+ regulatory T cell function | |
Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. | |
Effects of partial ileocolectomy and Crohn's disease on biliary lipid secretion | |
Effects of T cell-induced colonic inflammation on epithelial barrier function. | |
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed | |
Effects on bowel motility of misoprostol administered before and after meals | |
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies | |
Efficacy and safety of hydrostatic balloon dilation of ileocolonic Crohn's strictures. A prospective long-term analysis | |
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series | |
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial | |
Endoscopic injection therapy to prevent rebleeding from peptic ulcers with a protruding vessel: a controlled comparative trial | |
Endoscopic sclerotherapy of esophageal varices. Long-term follow-up, recurrence, and survival | |
Endoscopic therapy of strictures in Crohn's disease | |
Environmental Factors in Familial Crohnʼs Disease in Belgium | |
Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's disease | |
Erratum: Corrigendum: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 | |
Esophageal metastasis from breast carcinoma | |
Estrogen-progesterone treatment of Osler-Weber-Rendu disease | |
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial | |
Evaluation of early treatment response and predicting the need for colectomy in active ulcerative colitis with 99mTc-HMPAO white blood cell scintigraphy. | |
Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women | |
Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy | |
Exclusion of linkage of Crohn's disease to previously reported regions on chromosomes 12, 7, and 3 in the Belgian population indicates genetic heterogeneity | |
Experimental studies of injection therapy for severe nonvariceal bleeding in dogs. | |
Expression of MHC Class II antigens by oesophageal epithelium in herpes simplex oesophagitis | |
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study | |
Factors associated with short- and long-term outcomes of therapy for Crohn's disease | |
Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. | |
Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohnʼs disease | |
Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. | |
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study | |
Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease | |
Ileoscopy [VR] c1983: | |
An insertion-deletion polymorphism in the interferon regulatory Factor 5 | |
Leven met langdurige darmziekten : een gids voor patiënten en hun familie : hoe worden Crohn en colitis ulcerosa behandeld? : hoeveel kans maak je op een 'definitieve genezing'? | |
A novel hybrid technique using transanal endoscopic microsurgery and balloon dilation in the treatment of a benign complete colorectal anastomotic stricture | |
A phase II study of laquinimod in Crohn's disease | |
A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis | |
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism | |
A randomized trial comparing injection therapy with hemoclip and with injection combined with hemoclip for bleeding ulcers | |
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease | |
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease | |
Transcending therapeutic conventions : new realities in the treatment of Crohn's disease | |
Whipple’s disease: endoscopic aspects before and after therapy |